228 related articles for article (PubMed ID: 34518943)
1. PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.
Balhara A; Singh S
Pharm Res; 2021 Sep; 38(9):1485-1496. PubMed ID: 34518943
[TBL] [Abstract][Full Text] [Related]
2. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.
Zabost A; Brzezińska S; Kozińska M; Błachnio M; Jagodziński J; Zwolska Z; Augustynowicz-Kopeć E
Biomed Res Int; 2013; 2013():853602. PubMed ID: 24383060
[TBL] [Abstract][Full Text] [Related]
3. Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients.
Fukino K; Sasaki Y; Hirai S; Nakamura T; Hashimoto M; Yamagishi F; Ueno K
J Toxicol Sci; 2008 May; 33(2):187-95. PubMed ID: 18544910
[TBL] [Abstract][Full Text] [Related]
4. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.
Cordes H; Thiel C; Aschmann HE; Baier V; Blank LM; Kuepfer L
Antimicrob Agents Chemother; 2016 Oct; 60(10):6134-45. PubMed ID: 27480867
[TBL] [Abstract][Full Text] [Related]
5. A Rapid Pharmacogenomic Assay to Detect
Verma R; Patil S; Zhang N; Moreira FMF; Vitorio MT; Santos ADS; Wallace E; Gnanashanmugam D; Persing DH; Savic RM; Croda J; Andrews JR
Am J Respir Crit Care Med; 2021 Dec; 204(11):1317-1326. PubMed ID: 34375564
[No Abstract] [Full Text] [Related]
6. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
Jing W; Zong Z; Tang B; Wang J; Zhang T; Wen S; Xue Y; Chu N; Zhao W; Huang H
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907179
[TBL] [Abstract][Full Text] [Related]
8. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.
Donald PR; Parkin DP; Seifart HI; Schaaf HS; van Helden PD; Werely CJ; Sirgel FA; Venter A; Maritz JS
Eur J Clin Pharmacol; 2007 Jul; 63(7):633-9. PubMed ID: 17505821
[TBL] [Abstract][Full Text] [Related]
9. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
[TBL] [Abstract][Full Text] [Related]
10. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
Cho YS; Jang TW; Kim HJ; Oh JY; Lee HK; Park HK; Ghim JL; Long NP; Park Y; Choi YK; Phuong NTT; Shin JG;
J Clin Pharmacol; 2021 Dec; 61(12):1567-1578. PubMed ID: 34157153
[TBL] [Abstract][Full Text] [Related]
11. [Cytochrome P450 and NAT2 polymorphisms and drug metabolism in DOTS].
Castillejos-López Mde J; García-Sancho MC; Quiñones-Falconi F; Pérez-Padilla JR
Rev Invest Clin; 2008; 60(1):47-57. PubMed ID: 18589587
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.
Desta Z; Soukhova NV; Flockhart DA
Antimicrob Agents Chemother; 2001 Feb; 45(2):382-92. PubMed ID: 11158730
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
[TBL] [Abstract][Full Text] [Related]
14. Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy.
Amaeze OU; Isoherranen N
Clin Transl Sci; 2023 Nov; 16(11):2163-2176. PubMed ID: 37712488
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
16. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.
Kita T; Tanigawara Y; Chikazawa S; Hatanaka H; Sakaeda T; Komada F; Iwakawa S; Okumura K
Biol Pharm Bull; 2001 May; 24(5):544-9. PubMed ID: 11379777
[TBL] [Abstract][Full Text] [Related]
17. Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe.
Aït Moussa L; Khassouani CE; Hüe B; Jana M; Bégaud B; Soulaymani R
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):548-53. PubMed ID: 12503812
[TBL] [Abstract][Full Text] [Related]
18. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
[TBL] [Abstract][Full Text] [Related]
19. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
Suvichapanich S; Fukunaga K; Zahroh H; Mushiroda T; Mahasirimongkol S; Toyo-Oka L; Chaikledkaew U; Jittikoon J; Yuliwulandari R; Yanai H; Wattanapokayakit S; Tokunaga K
Pharmacogenet Genomics; 2018 Jul; 28(7):167-176. PubMed ID: 29781872
[TBL] [Abstract][Full Text] [Related]
20. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients.
Sileshi T; Telele NF; Burkley V; Makonnen E; Aklillu E
Sci Rep; 2023 Jul; 13(1):11438. PubMed ID: 37454203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
